Maxim Group Reaffirms Buy Rating for Heart Test Laboratories (NASDAQ:HSCS)

Heart Test Laboratories (NASDAQ:HSCS)‘s stock had its “buy” rating reaffirmed by equities research analysts at Maxim Group in a research report issued on Wednesday,Benzinga reports. They presently have a $12.00 target price on the stock. Maxim Group’s price target indicates a potential upside of 204.57% from the stock’s current price.

Separately, Ascendiant Capital Markets reiterated a “buy” rating and issued a $15.00 price objective on shares of Heart Test Laboratories in a research note on Monday, September 23rd.

Heart Test Laboratories Trading Up 2.3 %

Heart Test Laboratories stock opened at $3.94 on Wednesday. Heart Test Laboratories has a one year low of $2.36 and a one year high of $18.50. The business’s fifty day moving average is $3.24 and its 200 day moving average is $3.79. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.49 and a quick ratio of 4.02. The stock has a market capitalization of $3.60 million, a PE ratio of -0.19 and a beta of 3.23.

Heart Test Laboratories (NASDAQ:HSCS) last released its quarterly earnings data on Monday, December 16th. The company reported ($2.27) earnings per share for the quarter, beating the consensus estimate of ($2.30) by $0.03. During the same quarter in the previous year, the firm earned ($15.92) EPS. On average, sell-side analysts predict that Heart Test Laboratories will post -9.82 EPS for the current year.

Heart Test Laboratories Company Profile

Heart Test Laboratories, Inc, a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals.